• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Document › Details

Wilex AG. (4/24/17). "Press Release: Wilex AG Plans Rights Issue Using Authorised Capital. Ad-hoc release [Not for distribution, publication or transmission in the USA, Canada, Japan and Australia]". Munich.

	Organisation	Wilex AG
	Today	Heidelberg Pharma AG (FSE: WL6)
	Group	Heidelberg Pharma (Group)
	Organisation 2	Dievini Hopp BioTech Holding GmbH & Co. KG
	Group	HOPP Group (family of Dietmar Hopp)
	Product	Antibody Targeted Amanitin Conjugate (ATAC)
	Product 2	investment banking
	Person	Wimmer, Sylvia (Wilex 201403 Corporate Communications)
	Person 2	Arnold, Katja (MC Services 201309 CIRO Executive Director before Wilex AG + CAT Consultants)

Record changed: 2017-05-02

Advertisement

More documents for Heidelberg Pharma (Group)

• [1] Hofmann, Siegfried / Brors, Peter. (12/5/18). "News: Interview – Dietmar Hopp glaubt an seine Biotechs – »Wir werden unseren Einsatz verdreifachen«"....
• [2] Heidelberg Pharma AG. (3/5/18). "Press Release: Heidelberg Pharma and Magenta Therapeutics Sign Exclusive MultiTarget Research Agreement for the Development of Antibody Drug Conjugates". Ladenburg & Cambridge, MA....
• [3] Heidelberg Pharma AG. (3/1/18). "Press Release: Heidelberg Pharma Signs License Agreement with The University of Texas MD Anderson Cancer Center". Ladenburg....
• [4] Heidelberg Pharma AG. (10/19/17). "Press Release: Wilex AG Successfully Completes Change of Name to Heidelberg Pharma AG". Ladenburg....
• [5] Wilex AG. (10/9/17). "Press Release: Interim Management Statement for the First Nine Months of 2017". Munich....
• [6] Wilex AG. (10/9/17). "Press Release: Wilex AG Announces Adjustment of Guidance [Ad-hoc release – Insider information pursuant to Article 17 MAR]". Ladenburg....
• [7] Wilex AG. (7/13/17). "Press Release: Wilex Reports on First Half-year". Munich....
• [8] Wilex AG. (6/19/17). "Press Release: Wilex Subsidiary Heidelberg Pharma Signs Exclusive Multi-target Research Agreement with Takeda for the Development of Antibody Targeted Amanitin Conjugates". Munich....
• [9] Wilex AG. (4/12/17). "Press Release: Interim Management Statement on the First Three Months of 2017". Munich....
• [10] Wilex AG. (2/6/17). "Press Release: Wilex AG Secures Financing Commitment from Its Main Shareholder Dievini". Munich....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.